Department of Medicinal Chemistry, Amgen Inc., 1120 Veterans Blvd., South San Francisco, CA 94080, USA.
Bioorg Med Chem Lett. 2012 Sep 15;22(18):5966-70. doi: 10.1016/j.bmcl.2012.07.048. Epub 2012 Jul 21.
The present report describes our efforts to convert an existing LXR agonist into an LXR antagonist using a structure-based approach. A series of benzenesulfonamides was synthesized based on structural modification of a known LXR agonist and was determined to be potent dual liver X receptor (LXR α/β) ligands. Herein we report the identification of compound 54 as the first reported LXR antagonist that is suitable for pharmacological in vivo evaluation in rodents.
本报告描述了我们使用基于结构的方法将现有 LXR 激动剂转化为 LXR 拮抗剂的努力。根据已知 LXR 激动剂的结构修饰,合成了一系列苯磺酰胺,并被确定为有效的双肝 X 受体(LXRα/β)配体。在此,我们报告了化合物 54 的鉴定,它是第一个被报道的适合在啮齿动物中进行药理学体内评估的 LXR 拮抗剂。